Cytek Biosciences Operating Expenses 2021-2025 | CTKB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytek Biosciences operating expenses from 2021 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Cytek Biosciences Operating Expenses 2021-2025 | CTKB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytek Biosciences operating expenses from 2021 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$243.4B
Amgen (AMGN)	$156.3B
Gilead Sciences (GILD)	$147.7B
Vertex Pharmaceuticals (VRTX)	$100.1B
Bristol Myers Squibb (BMY)	$97.3B
CSL (CSLLY)	$85B
GSK (GSK)	$80B
Regeneron Pharmaceuticals (REGN)	$60B
Alnylam Pharmaceuticals (ALNY)	$58B
Argenex SE (ARGX)	$39.9B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$20.5B
Biogen (BIIB)	$19.8B
Incyte (INCY)	$16.8B
Illumina (ILMN)	$15.4B
Genmab (GMAB)	$14.7B
Genmab (GNMSF)	$14.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.4B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B
Halozyme Therapeutics (HALO)	$7.7B